STDY - SteadyMed Ltd.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
4.725
-0.025 (-0.53%)
As of 4:00PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close4.750
Open4.750
Bid0.000 x 1800
Ask0.000 x 800
Day's Range4.675 - 4.775
52 Week Range2.600 - 4.800
Volume674,420
Avg. Volume96,805
Market Cap126.36M
Beta (3Y Monthly)0.16
PE Ratio (TTM)N/A
EPS (TTM)-0.637
Earnings DateNov 12, 2018 - Nov 16, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est15.00
Trade prices are not sourced from all markets
  • United Therapeutics (UTHR) Up 0.4% Since Last Earnings Report: Can It Continue?
    Zacks2 months ago

    United Therapeutics (UTHR) Up 0.4% Since Last Earnings Report: Can It Continue?

    United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • PR Newswire2 months ago

    United Therapeutics Corporation Completes Acquisition Of SteadyMed Ltd.

    SILVER SPRING, Md. , Aug. 30, 2018 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) ("United Therapeutics") today announced that it has closed the merger of SteadyMed Ltd. (NASDAQ: ...

  • Zacks Small Cap Research2 months ago

    CORV: US Brinavess Launch Now Reflected

    Since our last report, Brinavess has been on a roll. Movement forward occurred in China, with partner Eddingpharm enrolling in its Phase III and the CFDA identifying the drug as clinically urgently needed. There was also advancement in the US with the FDA allowing for a pre-NDA meeting and resubmission of the NDA, which is expected to occur early next year.

  • GlobeNewswire2 months ago

    SteadyMed Provides Corporate Update and Reports Second Quarter 2018 Financial Results

    SAN RAMON, Calif., Aug. 14, 2018-- SteadyMed Ltd., a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and high-value diseases with unmet parenteral ...

  • United Therapeutics (UTHR) Q2 Earnings Flat Y/Y, Shares Dip
    Zacks2 months ago

    United Therapeutics (UTHR) Q2 Earnings Flat Y/Y, Shares Dip

    United Therapeutics (UTHR) reports unimpressive second-quarter earnings. Sales rise sequentially. Shares sink 5%.

  • GlobeNewswire3 months ago

    SteadyMed Shareholders Approve Proposed Acquisition by United Therapeutics

    SteadyMed Ltd. (STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and high-value diseases with unmet parenteral delivery needs, today announced that SteadyMed shareholders voted to approve the previously announced acquisition of the company by United Therapeutics Corporation (UTHR) at an extraordinary general meeting of shareholders held on July 30, 2018. Upon completion of the acquisition, SteadyMed shareholders will be entitled to receive $4.46 per share in cash and one contractual contingent value right per share (subject to the Contingent Value Rights Agreement), which will represent the right to receive $2.63 in cash upon the achievement of a milestone related to the commercialization of Trevyent®.

  • GlobeNewswire3 months ago

    HSR Act Waiting Period Terminated for United Therapeutics’ Acquisition of SteadyMed Ltd.

    As previously announced on April 30, 2018, United Therapeutics and SteadyMed entered into a definitive merger agreement under which United Therapeutics will acquire SteadyMed for $4.46 per share in cash at closing and one contractual contingent value right per share (subject to the Contingent Value Rights Agreement), which will represent the right to receive $2.63 in cash upon the achievement of a milestone related to the commercialization of Trevyent®. The termination of the waiting period under the HSR Act satisfies one of the conditions to closing of the acquisition, which remains subject to other closing conditions, including the approval of the acquisition by SteadyMed’s shareholders. A meeting of SteadyMed’s shareholders to vote upon the acquisition will be held on July 30, 2018.

  • PR Newswire3 months ago

    HSR Act Waiting Period Terminated for United Therapeutics' Acquisition of SteadyMed Ltd.

    As previously announced on April 30, 2018, United Therapeutics and SteadyMed entered into a definitive merger agreement under which United Therapeutics will acquire SteadyMed for $4.46 per share in cash at closing and one contractual contingent value right per share (subject to the Contingent Value Rights Agreement), which will represent the right to receive $2.63 in cash upon the achievement of a milestone related to the commercialization of Trevyent®. The termination of the waiting period under the HSR Act satisfies one of the conditions to closing of the acquisition, which remains subject to other closing conditions, including the approval of the acquisition by SteadyMed's shareholders. A meeting of SteadyMed's shareholders to vote upon the acquisition will be held on July 30, 2018.

  • Top High Growth Stocks This Week
    Simply Wall St.4 months ago

    Top High Growth Stocks This Week

    Investors tend to look for stocks that have a strong future outlook. Why invest in something that will grow slower than the rest of the market? In terms of profitabilityRead More...

  • PR Newswire4 months ago

    SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of SteadyMed Ltd. - STDY

    NEW YORK , June 13, 2018 /PRNewswire/ --  Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York ...

  • Zacks Small Cap Research5 months ago

    CORV: Cipher Transaction Done; Focus Back to Europe

    During the first quarter and to date, Correvio announced a strategic transaction with Cipher (CPH.TO) and subsequently closed it, changing their name and ticker symbol in the process. Importantly, as part of the transaction with Cipher, Correvio has received about US$20 million, which should provide sufficient capital to achieve operationally breakeven levels. Sales, general and administrative expenses were $10.9 million, increasing 33% as the company increased the size of its European direct sales force and the recognition of business development and transaction costs related to the Cipher transaction.

  • CNW Group5 months ago

    Correvio Reports First Quarter 2018 Financial Results

    Correvio Reports First Quarter 2018 Financial Results

  • Best NasdaqGM Growth Companies
    Simply Wall St.5 months ago

    Best NasdaqGM Growth Companies

    Looking to add potential meaningful upside to your portfolio, but unsure where to start? Stocks such as SteadyMed and SiteOne Landscape Supply are considered to be high growth in termsRead More...

  • Business Wire5 months ago

    The Law Offices of Vincent Wong Notifies Investors of an Investigation into SteadyMed Ltd. in Connection with the Sale of the Company to United Therapeutics Corporation – STDY

    The Law Offices of Vincent Wong are investigating the Board of Directors of SteadyMed Ltd. for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to United Therapeutics Corporation.

  • Pharma Stock Roundup: Mixed Q1 for MRK, PFE, FDA Nod for Kymriah's 2nd Indication
    Zacks5 months ago

    Pharma Stock Roundup: Mixed Q1 for MRK, PFE, FDA Nod for Kymriah's 2nd Indication

    Earnings are in focus this week with Pfizer (PFE) and Merck (MRK) delivering mixed Q1 numbers. Novartis gains FDA approval for the second indication of its CAR-T therapy, Kymriah.

  • ACCESSWIRE5 months ago

    SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces an Investigation of SteadyMed Ltd.- STDY

    BALA CYNWYD, PA / ACCESSWIRE / May 3, 2018 / Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of SteadyMed Ltd. ("SteadyMed" or "the Company") (NASDAQ:STDY News) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the sale of the Company to United Therapeutics Corporation. Under the terms of the transaction, SteadyMed shareholders will receive only $4.46 in cash and an additional $2.63 in cash upon achievement of certain milestone related to SteadyMed's Trevyent drug-device combination product for each share of SteadyMed stock they own. The investigation concerns whether the Board of SteadyMed breached their fiduciary duties to shareholders and whether United Therapeutics is underpaying for the Company.

  • Business Wire5 months ago

    INVESTOR ALERT: Brower Piven Commences an Investigation into the Proposed Sale of SteadyMed Ltd. and Encourages Shareholders to Contact the Firm for Additional Information

    The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of SteadyMed Ltd. (STDY) (“SteadyMed” or the “Company”) relating to the proposed buyout of SteadyMed by United Therapeutics Corporation. Under the terms of the agreement, SteadyMed shareholders are anticipated to receive $4.46 per share in cash, with an additional $2.63 per share in cash upon achievement of a certain milestone related to SteadyMed’s Trevyent drug-device combination product for each share of SteadyMed common stock held.

  • PR Newswire6 months ago

    WeissLaw LLP Investigates SteadyMed Ltd.

    NEW YORK , May 2, 2018 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of SteadyMed Ltd. ("STDY" or the ...

  • ACCESSWIRE6 months ago

    Blog Exposure - United Therapeutics Acquired SteadyMed for Approximately $216 Million

    LONDON, UK / ACCESSWIRE / May 02, 2018 / Active-Investors.com has just released a free research report on United Therapeutics Corp. (NASDAQ: UTHR). On April 30, 2018, United Therapeutics and SteadyMed Ltd (NASDAQ: STDY) announced the signing of a definitive merger agreement under which United Therapeutics will acquire SteadyMed for $4.46 per share in cash at closing and an additional $2.63 per share in cash upon the achievement of a milestone related to the commercialization of Trevyent®. The transaction, including the $75 million in contingent consideration, is valued at $216 million.

  • ACCESSWIRE6 months ago

    Today’s Research Reports on Stocks to Watch: Atossa Genetics and SteadyMed

    NEW YORK, NY / ACCESSWIRE / May 1, 2018 / Pharma stocks Atossa Genetics and SteadyMed were seeing big gains in Monday trading after each company announced big news. Atossa has received approval from the ...

  • ACCESSWIRE6 months ago

    SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of SteadyMed Ltd.- STDY

    BALA CYNWYD, PA / ACCESSWIRE / April 30, 2018 / Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of SteadyMed Ltd. ("SteadyMed" ...

  • Business Wire6 months ago

    SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of SteadyMed Ltd. And Encourages Investors To Contact The Firm For Additional Information

    The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of SteadyMed Ltd. (STDY) (“SteadyMed” or the “Company”) relating to the proposed buyout of SteadyMed by United Therapeutics Corporation. Under the terms of the agreement, SteadyMed shareholders are anticipated to receive $4.46 per share in cash, with an additional $2.63 per share in cash upon achievement of a certain milestone related to SteadyMed’s Trevyent drug-device combination product for each share of SteadyMed common stock held.